Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Cost for persons with diabetes and their families
- Loss of income for persons with diabetes in US
- Higher health care expenses to the family
- Percent of income spent on diabetes care in India
- Annual out-of-pocket health expenditure
- Financial burden and diabetes (1)
- Financial burden and diabetes (2)
- Higher non-medical expenditures
- Loss of life
- Worse quality of life
- Reduction in CVD and disability free years
- SF-36 domains and summary scores
- Health-related quality of life with/without diabetes
- Health utility
- Health utility scores for persons with diabetes
- Costs of diabetes to employers in US (1)
- Costs of diabetes to employers in US (2)
- Loss in productivity to employers in the US
- Total costs of diabetes to employers in US (2010)
- Economic costs to health care system
- Per capita prevalence-based estimates
- Medical expenditures for persons with diabetes
- Global health care expenditure on diabetes (1)
- Economic costs of diabetes in US in 2012
- Medical costs of treatment and complications
- Per capita incidence-based estimates
- Life time medical cost of a person with T1D
- Life time medical cost of a person with T2D
- Economic model of health care burden of T2D
- Aggregate prevalence-based estimates
- Global health care expenditure on diabetes (2)
- Global health care expenditure on diabetes (3)
- Expenditures by type of service in US, 2012
- Expenditures by medical conditions in US, 2012
- Increases in medical costs of diabetes
- Economic cost of diabetes to society
- Cost-of-illness approach
- Economic cost of diabetes in US, 2012 (flowchart)
- Increases in total economic costs of diabetes
- Economic growth
- Loss of gross domestic product (GDP)
- Loss of GDP due to diabetes, 2010-2030
- Economic cost of diabetes to society
- Mortality attributable to diabetes
- Estimated global disability life years to diabetes
- “Best buy” interventions
- Conclusions
Topics Covered
- Economic cost and social cost of diabetes
- measuring the burden of diabetes on persons with the disease, the health care system, business, and society as a whole in both monetary term and social terms
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Zhang, P. (2014, January 5). Economic and social cost of diabetes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/QPAK4091.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Ping Zhang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Economic and social cost of diabetes
Published on January 5, 2014
48 min
A selection of talks on Cardiovascular & Metabolic
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, my name is Ping Zhang.
I'm a senior economist from the Division of Diabetes Translation,
Centers for Disease Control and Prevention in the United States.
If you have any questions regarding this presentation,
please send me an email at pzhang@CDC.gov.
In this presentation, I'm going to talk about
economic and social costs of diabetes.
0:30
Here is a brief outline for my presentation.
I will describe the cost of diabetes from 4 different perspectives—
the cost borne by persons with diabetes and their families,
employer or business,
health care system, and society as a whole.
For each perspective, I will describe the cost in 2 different terms—
economic terms, which measure the cost in monetary value—
non-economic or social terms, which measure the cost in health terms,
such as mortality and health-related quality of life,
or other terms, such as social justice.
As the cost estimate from each perspective can be varied,
but country citing depends on many factors—
such as country's income level, healthcare utilization patterns,
and the cost of service, healthcare finance and tax structure.
All the estimates I presented here
are based on the current U.S. situation
unless I specify.
1:37
The cost of diabetes for a person with the disease and their families—
in economic terms, the cost can be divided into 3 categories.
Loss in personal or family income,
higher medical expenditures,
and higher non-medical expenditures,
all in comparison with a similar person without diabetes.
In non-economic terms,
the cost can be measured in terms of mortality—
that is the loss of life years—
and the morbidities—that is a lower quality of life.